AB0700 TOCILIZUMAB DID NOT REDUCE MORTALITY IN SEVERE COVID-19 PATIENTS BUT CAUSED THROMBOCYTOSIS

Background: TCZ is a monoclonal antibody against Interleukin-6 receptor (IL-6R) which used for relieving inflammation and reducing mortality in COVID-19 patients. Safety efficacy of Tocilizumab (TCZ) Covid-19 pneumonia uncertain yet. In this study, we aimed to determine clinical outcomes patients treated with TCZ. Objectives: study share our retrospective results had obtained from diagnosis received Methods: We performed case control between May August 2020 Turkey. compared who those did not. Death hospital intensive care unit (ICU) requirements were evaluated as endpoints. Demographic data, comorbidities, additional treatment, treatment side effects, laboratory retrospectively assessed. There are no significant differences groups according age, gender Charlson Comorbidity Index (CCI). Results: 12 (27.3%) died standard group eight (18.6%) (p=0.150).Days staying the days (p=0.03). 10 43 admitted ICU. MV support was needed 8 these 18 44 (40.9%) within ICU intubated (p=0.125,p=0.480). Significant IL-6 decrease not observed post pretreatment period (p=0.60). decreases examined CRP ferritin values through treatment. However, D-dimer thrombocyte increased. Conclusion: may be an effective requirement, prevent intubation or death, shortening hospital. The should followed up closely possible thrombosis because increased thrombocytes References: [1]Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2): A global pandemic strategies. IntJ Antimicrob Agents. Aug; 56(2):106054. [2]Singhal T. rewiev coronavirus Disease-2019(COVID-19). Indian J Pediatr. Apr;87(4):281-286. [3]Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall R.S, Manson J.J. COVID-19: consider cytokine storm syndromes immunosuppression. Lancet. 2020;395(10229):1033- [4]Teijaro J.R. Cytokine storms infectious diseases. SeminImmunopathol. 2017;39:501–503. [5]Zhang Y, Li J, Zhan Wu L, Yu X, Zhang W et al. Analysis Serum Cytokines Patients Acute Respiratory Syndrome. Infect Immun 2004 Aug;72(8):4410-4415. [6]Zhang C, Z, JW, Zhao H, Wang GQ. release severe interleukin-6 antagonist tocilizumab key reduce mortality. Int May; 55(5):105954. [7]Xu Shi Huang C Pathological findings associated distress syndrome. Lancet Respir Med. 2020;8(4):420–2 [8]Fu B, Xu Wei H. Why could COVID-19? Transl Med 18,164 (2020). [9]Guaraldi G, Meschiari Cozzi-Lepri Milic Tonelli R, Menozzi M cohort study. Rheumatol. Aug;2(8):e474-e484. [10]Gupta W, Hayek S.S, Chan MathewsK.S, Melamed M.L Association Between Early Treatment With Mortality Among Critically Ill COVID-19. JAMA Intern 2021 Jan1;181(1):41-51. [11]Campochiaro Della-Torre Cavalli De Luca Ripa Boffini N al Efficacy safety COVID- 19 patients: single-centre Eur Jun;76:43-49. Disclosure Interests: None declared